Literature DB >> 29906430

Five-Year Postoperative Outcomes of Bilateral Aphakia and Pseudophakia in Children up to 2 Years of Age: A Randomized Clinical Trial.

Abhay R Vasavada1, Vaishali Vasavada2, Sajani K Shah2, M R Praveen2, Viraj A Vasavada2, Rupal H Trivedi3, Farida Rawat2, Archana Koul2.   

Abstract

PURPOSE: Comparative evaluation of complications and visual outcomes following bilateral congenital cataract surgery in children up to 2 years of age with and without primary intraocular lens (IOL) implantation at 5 years follow-up.
DESIGN: Randomized controlled clinical trial.
METHODS: Sixty children (120 eyes) up to 2 years of age undergoing bilateral congenital cataract surgery were randomized to Group 1, primary aphakia (n = 30), or Group 2, primary IOL implantation (pseudophakia) (n = 30). A single surgeon performed surgeries with identical surgical technique. All patients were followed up regularly until 5 years postoperatively. At each follow-up, glaucoma, visual axis obscuration (VAO) requiring surgery, and inflammation (cell deposits, posterior synechiae) were assessed. Visual acuity was assessed until 5 years follow-up. The first operated eye was selected for statistical analysis.
RESULTS: Median age of the patients at time of surgery was 5.11 months (aphakia group) and 6.01 months (pseudophakia group) (P = .56). Five years postoperatively, incidence of glaucoma was 16% and 13.8% in Groups 1 and 2 (P = .82). Incidence of posterior synechiae was significantly higher in the pseudophakia group (27.6%) compared to the aphakia group (8%) (P = .004). VAO requiring surgery was seen in 8% and 10.3% of eyes in Groups 1 and 2 (P = .76). Mean logMAR visual acuity at 5 years follow-up was 0.59 ± 0.33 and 0.5 ± 0.23 in Groups 1 and 2, respectively (P = .79). However, more eyes in the pseudophakic group started giving documentable vision earlier in their postoperative follow-ups.
CONCLUSIONS: Incidence of postoperative complications was comparable between the groups, except for a higher incidence of posterior synechiae in pseudophakic eyes. Visual rehabilitation was faster in the pseudophakic group.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29906430     DOI: 10.1016/j.ajo.2018.06.005

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

Review 1.  Surgical interventions for bilateral congenital cataract in children aged two years and under.

Authors:  Ritvij Singh; Lucy Barker; Sean I Chen; Anupa Shah; Vernon Long; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2022-09-15

2.  Five-Year Postoperative Outcomes of Bilateral Aphakia and Pseudophakia in Children up to 2 Years of Age: A Randomized Clinical Trial.

Authors:  Scott R Lambert; Erick D Bothun; David A Plager
Journal:  Am J Ophthalmol       Date:  2018-12-19       Impact factor: 5.488

3.  The mutation spectrum in familial versus sporadic congenital cataract based on next-generation sequencing.

Authors:  Fan Fan; Yi Luo; Jihong Wu; Chao Gao; Xin Liu; Hengjun Mei; Xiyue Zhou
Journal:  BMC Ophthalmol       Date:  2020-09-03       Impact factor: 2.209

4.  The role of primary intraocular lens implantation in the risk of secondary glaucoma following congenital cataract surgery: A systematic review and meta-analysis.

Authors:  Shuo Zhang; Jiaxing Wang; Ying Li; Ye Liu; Li He; Xiaobo Xia
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

5.  Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series.

Authors:  Mari Kathrine Sand; Symira Cholidis; Kjartan Rimstad; Elise Dees Krekling; Olav Kristianslund; Liv Drolsum
Journal:  BMJ Open Ophthalmol       Date:  2021-09-30

6.  Posterior Capsular Outcomes of Pediatric Cataract Surgery With In-The-Bag Intraocular Lens Implantation.

Authors:  Yana Fu; Dandan Wang; Xixia Ding; Pingjun Chang; Yinying Zhao; Man Hu; Zhangliang Li; Yun-E Zhao
Journal:  Front Pediatr       Date:  2022-04-08       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.